Drug trial aims to shield patients from harsh chemo side effects while fighting bladder cancer
Disease control
Terminated
This study tested if adding a drug called trilaciclib to standard first-line chemotherapy and immunotherapy could better control advanced bladder cancer. The goal was to see if trilaciclib could help patients live longer without their cancer worsening while also protecting their …
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC